The novel ATP-competitive mTOR inhibitors (e. g., Torin1, PP242, ku-0063794, and WAY-600), which inhibit both mTORC1 and mTORC2, exert marked effects on protein synthesis, cell growth, and cell proliferation, and strongly promote autophagy in various cancer cell types in vitro[32], [42]. Here, MTOR is linked to cancer.